Borghaei H et al. Phase 1 updated exploration and first expansion data for DLL3-targeted T-cell engager tarlatamab in small cell lung cancer. IASLC 2022;Abstract OA12.05.
Bushunow P et al. EMERGE 402: Preliminary real-world characteristics and safety of lurbinectedin in patients with small-cell lung cancer. IASLC 2022;Abstract P2.10-02.
Calles A et al. A phase 1/2 trial of lurbinectedin (l) in combination with pembrolizumab (p) in relapsed small cell lung cancer (SCLC): The LUPER study. ASCO 2022;Abstract 8581.
Cargill KR et al. Alternative energy: Breaking down the diverse metabolic features of lung cancers. Front Oncol 2021;11:757323. Abstract
Cheng Y et al. Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study. ASCO 2022;Abstract 8505.
Estrin A et al. Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin. ESMO 2022;Abstract 1539P.
Gay C et al. SCLC subgroups and their potential clinical significance. IASLC 2021;Abstract ES11.01.
Gay CM et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 2021;39(3):346-60.e7. Abstract
Kundu K et al. SLFN11 biomarkers status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. Transl Lung Cancer Res 2021;10(11):4095-105. Abstract
Leventakos K et al. MC1923 phase ii clinical trial of durvalumab (MEDI4736) and topotecan or lurbinectedin in patients with relapsed extensive-stage small cell lung cancer previously treated with chemotherapy and immunotherapy. ASCO 2022;Abstract TPS8604.
Liu SV et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (Impower133). J Clin Oncol 2021;39(6):619-30. Abstract
Longo-Muñoz F et al. Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. Eur J Cancer 2022;172:340-48. Abstract
Manzo A et al. Lurbinectedin in small cell lung cancer. Front Oncol 2022;12:932105. Abstract
Navarro A et al. Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial. ASCO 2022;Abstract 8524.
Owonikoko TK et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol 2021;39(12):1349-59. Abstract
Paz-Ares L et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 2022;7(2):100408. Abstract
Paz-Ares L et al. IMforte: A phase III study of lurbinectedin and atezolizumab versus atezolizumab as maintenance therapy in ES-SCLC. IASLC 2022;Abstract EP14.01-015.
Paz-Ares L et al. Lurbinectedin/doxorubicin versus CAV or topotecan in relapsed SCLC patients: Phase III randomized ATLANTIS trial. IASLC 2021;Abstract PL02.03.
Rajpu PS et al. Treatment of small cell lung cancer with lurbinectedin: A review. Anticancer Agents Med Chem 2022;22(5):812-20. Abstract
Reinmuth N et al. LUMINANCE: A phase IIIb study of durvalumab plus platinum-etoposide for the first-line treatment of extensive-stage SCLC. IASLC 2022;Abstract EP14.05-015.
Rudin CM et al. First-line pembrolizumab or placebo combined with etoposide and platinum for ES-SCLC: KEYNOTE-604 long-term follow-up results. IASLC 2022;Abstract OA12.06.
Rudin CM et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol 2020;38(11):2369-79. Abstract
Rudin CM et al. SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC). ASCO 2022;Abstract LBA8507.
Spigel DR et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol 2021;32(5):631-41. Abstract
Toublanc A-C et al. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice. Thorac Cancer 2022;13(15):2248-52. Abstract
Trigo J et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020;21(5):645-54. Abstract
Wang J et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23(6):739-47. Abstract
Wang X et al. Characterization of real-world use of lurbinectedin in adult small cell lung cancer patients in the United States. IASLC 2022;Abstract EP14.05-023.
Weiss J et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: Pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer 2021;22(5):449-60. Abstract
Zehn DB et al. SWOG S2012: Randomized phase II/III trial of first line platinum platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated, extrapulmonary small cell neuroendocrine carcinomas (NEC). ASCO 2022;Abstract TPS4179.
Zhou N et al. Predictors of survival following surgical resection of limited-stage small cell lung cancer. J Thorac Cardiovasc Surg 2021;161(3):760-71.e2. Abstract